Maintenance treatment of multiple myeloma
- 1 December 1989
- journal article
- review article
- Published by Wiley in European Journal of Haematology
- Vol. 43 (S51) , 145-151
- https://doi.org/10.1111/j.1600-0609.1989.tb01508.x
Abstract
In multiple myeloma (MM), low-cost maintenance treatment has some attractions, since maintenance of a small tumor is usually compatible with a fairly healthy state. However, the great majority of the studies of maintenance treatment have failed to show any clinical benefit. Based on simple theoretical consideration, it is shown that in MM response duration and survival are affected primarily by the residual tumor mass after primary treatment, and by the kinetics of the tumor. Continuation of maintenance treatment is likely to have a moderate effect. The main cause of that is identified in the presence or in the development of a substantial proportion of drug-resistant cells. Preliminary data suggest that only alpha-interferon can be useful for maintenance, and that it can act by slowing down the kinetics of the tumor.Keywords
This publication has 25 references indexed in Scilit:
- Multiple myeloma in central and northern Norway 1981-1982: A follow-up study of a randomized clinical trial of 5-drug combination therapy versus standard therapyEuropean Journal of Haematology, 2009
- Results of the mrc myelomatosis trials for patients entered since 1980Hematological Oncology, 1988
- Chemotherapy of myeloma: Drug combinations versus single agents, an overview, and comments on acute leukemia in myelomaHematological Oncology, 1988
- Multiple myeloma treated with high dose intravenous melphalanBritish Journal of Haematology, 1987
- Multiple myeloma treated with high dose intravenous melphalanBritish Journal of Haematology, 1987
- Treatment of multiple myeloma with an intensive 5‐drug combination or intermittent melphalan and prednisone; a randomised multicentre trialEuropean Journal of Haematology, 1987
- Multiple myeloma: Current therapy and a glimpse of the futureScandinavian Journal of Haematology, 1985
- A methodological evaluation of 14 controlled clinical trials in myelomatosisScandinavian Journal of Haematology, 1985
- REAPPRAISAL OF PLATEAU PHASE IN MYELOMAThe Lancet, 1980
- Quantitation of Differential Sensitivity of Human-Tumor Stem Cells to Anticancer DrugsNew England Journal of Medicine, 1978